Open AccessROLE OF ESTROGEN RECEPTOR BETA IN THE DEVELOPMENT AND TREATMENT OF BREAST CANCER
Author(s) -
M. V. Rodionova,
И. К. Воротников,
В В Родионов,
N. V. Chkhivadze,
E. A. Dudko,
D. A. Ryabchikov,
Е. В. Ошкина,
Т. А. Богуш
Publication year - 2015
Publication title -
rossijskij bioterapevtičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 1726-9792
pISSN - 1726-9784
DOI - 10.17650/1726-9784-2015-14-2-39-46
Subject(s) - estrogen receptor , tamoxifen , breast cancer , antiestrogen , estrogen , estrogen receptor beta , receptor , carcinogenesis , selective estrogen receptor modulator , cancer , cancer research , beta (programming language) , medicine , oncology , computer science , programming language
Estrogen receptors are one of the major targets in cancer cells, acting on which it is possible not only to control the processes of carcinogenesis, but also to inhibit tumor cells growth. Brilliant confirmation of this is the results of long-term application of the first targeted therapy - antiestrogen tamoxifen - in breast cancer patients with positive hormonal status of the tumor. Being discovered in the 90s, estrogen receptor beta enhanced the understanding of estrogen-mediated signaling pathway and receptor-related interactions. This review of the literature presents data on the history of the discovery, structure and functional activity of selective estrogen receptor beta, and the results of existing clinical trials which have shown the predictive role of this marker.